



## NEWS RELEASE

### **For Further Information Contact:**

Roy Wolvin  
Nymox Pharmaceutical Corporation  
1-800-93NYMOX  
www.nymox.com

### **For Immediate Release:**

## **Nymox Reports Third Quarter 2006 Financial Results**

**Company reports successful Phase 2 trial results for new drug for benign prostatic hyperplasia; and 40 % increase in product sales results.**

HASBROUCK HEIGHTS, NJ (November 13, 2006) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today its financial results for the third quarter of 2006. Nymox reported a net loss of \$1,238,833, or \$0.04 per share for the quarter ending September 30, 2006, compared to \$958,464, or \$0.04 per share for same period in 2005. The increase in the net loss is attributable to stock-based compensation costs (\$282,063 compared to \$4,055 for the same period in 2005) and to an increase in research and development expenditures (15% increase compared to the same period in 2005). Product sales amounted to \$141,013 for the third quarter of 2006, compared to \$100,110 for the same period in 2005. Nymox currently has \$9.45 million in financing available from its most recent October 21, 2005 financing. The weighted diluted average number of common shares for the quarter ending September 30, 2006 was 27,789,196, compared to 25,916,670 for the same period in 2005.

Nymox has developed NX-1207, an innovative new treatment for BPH. The company's recently completed Phase 2 trial showed positive efficacy and safety results for NX-1207. Overall, patients treated with NX-1207 showed mean improvement of 9.35 points in AUA Symptom Score values, the standard scale used to evaluate BPH drugs and treatments. This improvement compares favorably to the 3.5 to 5 point reported in published studies of currently approved drugs for BPH and reached statistical significance when compared to placebo. Subjects treated with NX-1207 also showed an overall significant reduction in mean prostate volume. The results of the trial demonstrated the excellent safety and side effect profile of NX-1207. Subjects treated with NX-1207 had no serious side effects. In particular, patients given NX-1207 had no (0%) significant sexual side effects.

More information about Nymox is available at [www.nymox.com](http://www.nymox.com), email: [info@nymox.com](mailto:info@nymox.com), or 800-936-9669.

*This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.*

###